KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31

KAMADA LTD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026

$7.61−0.15 (-1.93%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 21.7
Dividend yield: –

Dividends

Kamada has not reported a dividend

No dividend per share appears in Kamada's annual filings since fiscal 2014.

Where these numbers come from

Parsed from the XBRL in Kamada's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KMDA.

Revenue growth13.2% · median 7.5%

Gross margin40.8% · median 85.5%

Operating margin14.5% · median 31.5%

Company	Revenue	Growth
LGND	$290.54M	+54.9%
RIGL	$276.79M	+3.3%
AKBA	$219.06M	+7.5%
KMDA	$191.85M	+13.2%
INCR	–	–
PHAR	–	–

Company

Next earnings (est.): Nov 9, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 393
Auditor: KOST FORER GABBAY & KASIERER
SEC CIK: 1567529

Advertisement
300 × 250